Biotechnology
Three Study Results Abstracts From Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) At 2024 ESMO Released Today
CHENGDU, China, Sept. 9, 2024 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2024 will be held inBarcelona, Spain from September 13 to 17, 2024. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd（"Kelun-Biotech", 6990.HK）will present the following results of its anti-TROP...
2024-09-09 14:27
1162
Antennova to Present Latest Data of ATN-037 in a Mini Oral Presentation at ESMO Congress 2024
BOSTON, Sept. 8, 2024 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced thatit will present the latest data of CD73 small molecule inhibitor ATN-037 in a Mini Oral presentation at the 2024 European Society of Medical Oncology Congress (ESMO Congress 2...
2024-09-09 08:30
1076
ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress
ROCKVILLE, Md. and SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malignancies, today announced that it will present the latest c...
2024-09-09 08:25
1563
Sciwind Biosciences Announces Oral Presentations at the European Association for the Study of Diabetes 60th Annual Meeting (EASD 2024)
HANGZHOU, China and SAN FRANCISCO, Sept. 6, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that the company will present positive results from a ...
2024-09-06 10:10
1916
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation
* Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human mini-heart drug discovery and screening technology platforms * Transactio...
2024-09-05 20:00
2440
Grand launch | Sanyou Bio monkeypox antibody made a great breakthrough
SHANGHAI, Sept. 4, 2024 /PRNewswire/ -- On August 28, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced the launch of 65 kinds of monkeypox antibodies, antigens and cell lines, which has won wide praise from the public. Monkeypox human antibody, as the core product launched by Sanyo...
2024-09-05 08:00
1057
Carterra unveils its most sensitive biosensor platform; Carterra Ultra™ ushers in a new frontier in fragment and small molecule drug discovery
The new instrument enables high-throughput small and large molecule characterization in traditional and AI-driven workflows SALT LAKE CITY, Sept. 4, 2024 /PRNewswire/ -- Carterra Inc., the world leader in innovative technologies enabling high-throughput biology, today has launched Carterra Ultra...
2024-09-04 23:00
1909
TraceLink's Magnum Release of its Opus Platform Will Revolutionize Supply Chain Management by Enabling All Businesses to Digitalize their End-to-End Supply Networks
With real-time information from all supply chain partners, Supply Chain Managers can reduce inventory and stock-out while improving service levels and lead times BOSTON, Sept. 4, 2024 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the ...
2024-09-04 22:00
1549
Regenity Biosciences Receives Regulatory Approval for Collagen Dental Membrane in China After First-of-its-Kind Breakthrough Clinical Study
Multicenter Clinical Study Demonstrates Benefits of Regenity's Novel Crosslinked Collagen Membrane Compared to Geistlich Bio-Gide® Collagen Membrane and Enables Launch intoChina PARAMUS, N.J., Sept. 4, 2024 /PRNewswire/ -- Regenity Biosciences, a global leader in regenerative medicine and Linden...
2024-09-04 21:00
1236
Phesi Receives Frost & Sullivan's Global Enabling Technology Leadership Award for Revolutionizing Clinical Development with Its Trial Accelerator Platform
Phesi's Trial Accelerator™ Platform empowers trial sponsors to make informed decisions swiftly, expediting drug development timelines while upholding the highest standards of data integrity and patient-centricity SAN ANTONIO, Sept. 4, 2024 /PRNewswire/ -- Frost & Sullivan has recognized Phesi wi...
2024-09-04 21:00
1220
LakeShore Biopharma Announces Leadership Transitions
GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...
2024-09-04 20:00
1180
LakeShore Biopharma Announces Leadership Transitions
GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...
2024-09-04 20:00
1386
21st.BIO obtains self-affirmed GRAS status for its precision fermented beta-lactoglobulin: 21st.BIO customers can now enter the U.S. market with their own production using 21st.BIO technology
* 21st.BIO has earned a self-affirmed GRAS status for its animal-free beta-lactoglobulin ingredient, which customers can now launch inthe United States market. * 21st.BIO is helping customers bring products to market at an unprecedented pace, from initiation of development to market approval ...
2024-09-04 15:47
1348
Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma
SAN FRANCISCO and SUZHOU, China, Sept. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-09-04 08:00
3949
Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases
* Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases * Pfizer Ignite will also provide strategic advisory support for Acepodia's ongoing clinical programs,...
2024-09-04 05:00
1590
Albatroz Therapeutics Soars into Johnson & Johnson Innovation - JLABS Singapore
SINGAPORE, Sept. 3, 2024 /PRNewswire/ -- Albatroz Therapeutics, a biotechnology company developing novel therapies against cancer and other indications, today announced its membership of Johnson & Johnson Innovation – JLABS Singapore. "We are thrilled to join the vibrant life science community at...
2024-09-03 20:30
1849
Biostar Announces Completion of Patient Recruitment for US Phase 1 Clinical Study of Utidelone Capsule
SAN FRANCISCO, Sept. 3, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative oncology drugs, is pleased to announce...
2024-09-03 20:00
1217
Skyline Therapeutics' Novel Gene Therapy SKG1108 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa
BOSTON and SHANGHAI, Sept. 3, 2024 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) fo...
2024-09-03 18:00
1063
GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA
* Co-development of innovative new drug for the treatment of Fabry disease as "the world's first once-monthly subcutaneous treatment" * Improves efficacy compared to existing treatment for kidney function, vascular disease, and peripheral nerve disorders YONGIN, South Korea, Sept. 3, 2024 /PR...
2024-09-03 15:59
1193
Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate Syndromic PCR Diagnostic Assays
- Nature Awards MDx Impact Grants in partnership with Seegene extends commitment to external innovation. - Global research teams invited to submit proposals to develop new tests for human infectious diseases. Application deadline:December 2, 2024. - Nature Awards to lead the application and eva...
2024-09-02 21:00
2141
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8703
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5845
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5183